Amarin - The Science Of Lipid Therapy (Seite 109)
eröffnet am 03.01.14 20:10:32 von
neuester Beitrag 04.04.24 15:47:54 von
neuester Beitrag 04.04.24 15:47:54 von
Beiträge: 1.840
ID: 1.190.027
ID: 1.190.027
Aufrufe heute: 4
Gesamt: 156.400
Gesamt: 156.400
Aktive User: 0
ISIN: US0231112063 · WKN: A0NBNG · Symbol: EH3A
0,8629
USD
-11,51 %
-0,1122 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
06.05.24 · globenewswire  |
01.05.24 · globenewswire |
24.04.24 · globenewswire |
22.04.24 · globenewswire |
15.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8450 | +146,00 | |
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9235 | -16,88 | |
| 5,2500 | -19,23 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Uiuiui die lassen sich aber Zeit, mein Popcorn ist bald alle menno und was mach ich dann 
Antwort auf Beitrag Nr.: 62.155.649 von bernie55 am 13.12.19 19:14:43 Oha...😃
Antwort auf Beitrag Nr.: 62.155.625 von bernie55 am 13.12.19 19:13:50T1 Halt - News Pending
Trading is halted pending the release of material news.
Trading is halted pending the release of material news.
Antwort auf Beitrag Nr.: 62.155.625 von bernie55 am 13.12.19 19:13:50AMARIN HALTED !!!!!!!!!!!!
Trading Spotlight
Überragende Scripts, Über 80.000 pro Woche und dass ohne CV Label, grandios:
NORMALIZED Scripts Update for Week Ending 06/12
ATH Across the Board in Numbers
2nd ATH in TRx & Refills Market Share, 3rd ATH in Refills Market Share
V
TRx: 83,269 {vs 67,887; +22.70%} Sector +24.12% --- (9,995,466 vs 8,146,400) -- ATH
NRx: 37,735 {vs 29,849; +26.42%} Sector +28.84% --- (4,528,247 vs 3,581,885) -- ATH
Ref: 45,560 {vs 38,038; +19.78%} Sector +20.43% --- (5,467,219 vs 4,564,515) -- ATH
GenL
TRx: 65,439 {vs 51,932; +26.01%} (7,852,629 vs 6,231,865)
NRx: 30,129 {vs 22,878; +31.70%} (3,615,518 vs 2,745,325)
L
TRx: 993 {vs 810; +22.61%} (119,172 vs 97,196)
NRx: 432 {vs 284; +52.22%} (51,826 vs 34,047)
V TRx Market Share: 55.63% vs 56.28% --- 2nd ATH Market Share
V NRx Market Share: 55.25% vs 56.31% --- 3rd ATH Market Share
V Ref Market Share: 55.95% vs 56.25% --- 2nd ATH Market Share
For those interested in Old Scripts Numbers ATH in TRx & Refills Numbers– 2nd ATH in NRx Numbers;
V TRx 63,459 vs GL TRx 48,673 & L 627 -- ATH
V NRx 24,267 vs GL NRx 19,868 & L 233 -- 2nd ATH
V Refills 39,192 vs GL Refills 28,805 & L 394 -- ATH
NORMALIZED Scripts Update for Week Ending 06/12
ATH Across the Board in Numbers
2nd ATH in TRx & Refills Market Share, 3rd ATH in Refills Market Share
V
TRx: 83,269 {vs 67,887; +22.70%} Sector +24.12% --- (9,995,466 vs 8,146,400) -- ATH
NRx: 37,735 {vs 29,849; +26.42%} Sector +28.84% --- (4,528,247 vs 3,581,885) -- ATH
Ref: 45,560 {vs 38,038; +19.78%} Sector +20.43% --- (5,467,219 vs 4,564,515) -- ATH
GenL
TRx: 65,439 {vs 51,932; +26.01%} (7,852,629 vs 6,231,865)
NRx: 30,129 {vs 22,878; +31.70%} (3,615,518 vs 2,745,325)
L
TRx: 993 {vs 810; +22.61%} (119,172 vs 97,196)
NRx: 432 {vs 284; +52.22%} (51,826 vs 34,047)
V TRx Market Share: 55.63% vs 56.28% --- 2nd ATH Market Share
V NRx Market Share: 55.25% vs 56.31% --- 3rd ATH Market Share
V Ref Market Share: 55.95% vs 56.25% --- 2nd ATH Market Share
For those interested in Old Scripts Numbers ATH in TRx & Refills Numbers– 2nd ATH in NRx Numbers;
V TRx 63,459 vs GL TRx 48,673 & L 627 -- ATH
V NRx 24,267 vs GL NRx 19,868 & L 233 -- 2nd ATH
V Refills 39,192 vs GL Refills 28,805 & L 394 -- ATH
Amarin's Litigation Landscape: Mostly Successful, Clearing The Field For A Decade
Dec. 10, 2019 3:00 PM
Amarin Corporation plc (AMRN)
Summary
- Amarin has successfully cleared the market of various Vascepa competitors.
- Barring a few items, its strategy has been mainly successful.
- As such, it has a clear playing field for Vascepa for the next decade.
https://seekingalpha.com/amp/article/4311700-amarins-litigat…
Dec. 10, 2019 3:00 PM
Amarin Corporation plc (AMRN)
Summary
- Amarin has successfully cleared the market of various Vascepa competitors.
- Barring a few items, its strategy has been mainly successful.
- As such, it has a clear playing field for Vascepa for the next decade.
https://seekingalpha.com/amp/article/4311700-amarins-litigat…
Antwort auf Beitrag Nr.: 62.113.787 von Magnetfeldfredy am 09.12.19 15:24:39
Will Meade
Former PM at Goldman Sachs founded $1.4 billion hedge fund. Educated at the University of Chicago and Johns Hopkins SAIS. Former Edito
Will Meade
Former PM at Goldman Sachs founded $1.4 billion hedge fund. Educated at the University of Chicago and Johns Hopkins SAIS. Former Edito
Fehtl nur noch unsere Amarin, aber das wird deutlich teurer, hatte auch mal Arqule......
BPs auf vorweihnachtliche Shopping-Tour :
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen
GlobeNewswire•December 7, 2019
https://finance.yahoo.com/news/xbiotech-announces-agreement-…
Sanofi to Buy U.S. Biotech Firm for $2.5 Billion in Cancer Push
,Bloomberg•December 9, 2019
https://finance.yahoo.com/news/sanofi-buy-synthorx-2-5-06451…
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
MarketWatch•December 9, 2019
https://finance.yahoo.com/m/4b3125eb-204d-3393-a6f1-63bed2ad…
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen
GlobeNewswire•December 7, 2019
https://finance.yahoo.com/news/xbiotech-announces-agreement-…
Sanofi to Buy U.S. Biotech Firm for $2.5 Billion in Cancer Push
,Bloomberg•December 9, 2019
https://finance.yahoo.com/news/sanofi-buy-synthorx-2-5-06451…
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
MarketWatch•December 9, 2019
https://finance.yahoo.com/m/4b3125eb-204d-3393-a6f1-63bed2ad…
Durchsuchen
Amarin - The Science Of Lipid Therapy
